Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7802560 | 0.84 | KMT2A (0.35) | KMT2AOPRM1SLC6A4SLC6A3PIK3CD | |
| SCHEMBL12672112 | 0.84 | SLC6A4 (0.37) | KMT2AOPRM1SLC6A4SLC6A3PIK3CD | |
| SCHEMBL7814915 | 0.84 | KMT2A (0.35) | KMT2AOPRM1SLC6A4SLC6A3PIK3CD | |
| SCHEMBL332828 | 0.84 | SLC6A4 (0.37) | KMT2AOPRM1SLC6A4SLC6A3PIK3CD | |
| SCHEMBL7802557 | 0.84 | KMT2A (0.35) | KMT2AOPRM1SLC6A4SLC6A3PIK3CD | |
| SCHEMBL1598590 | 0.80 | KMT2A (0.41) | KMT2AOPRM1PIK3CDOPRL1OPRD1 | |
| SCHEMBL7809036 | 0.77 | KMT2A (0.31) | KMT2A | |
| SCHEMBL9098611 | 0.75 | ALOX5 (0.36) | — | |
| SCHEMBL12638709 | 0.74 | — | — | |
| SCHEMBL332497 | 0.70 | ALOX5 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1978966-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | Amira Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087250-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087250-A2 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | KMT2A 3956/4885OPRM1 1409/4885SLC6A4 2829/4885 |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | KMT2A 3956/4885OPRM1 1409/4885SLC6A4 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.